2004 pro forma combined net sales up 10.0% on a comparable basis

Sanofi-aventis gains market share from year one After consultation with the stock market authorities in France and the United States, sanofi-aventis has retained August 20 as the date of first consolidation. In 2004, sanofi-aventis generated consolidated net sales of 15,043 million euros compared with 8,048 million euros in 2003. In the fourth quarter of 2004, sanofi-aventis consolidated net sales were 6,614 million euros, against 2,108 million euros in the fourth quarter of 2003. Details of these figures are given in an appendix. In order to give a better representation of the business performance of the new Group, we have decided to publish and explain pro forma combined net sales of the new Group for the fourth quarter of 2004 and for the year ended December 31, 2004, along with comparatives for 2003. Combined pro forma sales are non-GAAP financial measures. Unless otherwise indicated, the growth figures given in this press release are on a comparable basis (see the explanatory notes). Year ended December 31, 2004 • Pro forma combined net sales: +10.0% at 25,418 million euros. • Pro forma combined developed sales2: +12.3% at 28,529 million euros. • Above-market growth increased the worldwide market share to 5.3%3 • Top 15 products grew at 17.8%, rest of the portfolio stable year-on-year • Continuing strong growth in US prescriptions of our products Fourth quarter of 2004 • Pro forma combined net sales: +8.1% at 6,614 million euros. • Pro forma combined developed sales2: +9.1% at 7,503 million euros. • Above-market growth in net sales. 1 Pro forma combined net sales represents sales generated by the Sanofi-Synthélabo and Aventis groups excluding net sales from products divested at the request of the antitrust authorities, which have been eliminated from the start of the periods presented, and also excluding the Aventis Behring business divested in March 2004. 2 Pro forma combined developed sales include pro forma combined sales recorded by sanofi-aventis and sales generated under the agreements with Bristol-Myers Squibb on Plavix®/Iscover® (clopidogrel) and Aprovel®/Avapro®/Karvea® (irbesartan), and with Fujisawa on Myslee®(zolpidem) (see explanatory notes) 3 Sanofi-aventis IMS MIDAS World all available channels: Rolling quarter November 2004 Senior Vice President, Corporate Communications: Nicole Cranois - Vice President, Media Relations: Jean-Marc Podvin Tel.:+33 1.53.77.42.23 - Fax: +33 1.53.77.42.65 - 174, avenue de FRANCE - 75013 Paris - France - www.sanofi-aventis.com See attachment for complete release.